Month: March 2020

First Study in the U.S. and Japan to Report Results on One-Month DAPT Duration in High Bleeding Risk Patients with Current-Generation DESDUBLIN, March 30, 2020 (GLOBE NEWSWIRE) —  Medtronic plc (NYSE:MDT) today announced positive results of the Onyx ONE Clear Study that evaluated Resolute Onyx DES in high bleeding risk (HBR) patients with one-month dual antiplatelet therapy (DAPT) in the United States and Japan. The study met its primary endpoint of cardiac death or myocardial infarction by beating a performance goal derived from contemporary one-month DAPT trials at one-year post-procedure. Results from the study were shared virtually at the American College of Cardiology together with the World Congress of Cardiology Scientific Sessions (ACC.20/WCC) on March 28, 2020.“Despite the high-risk population, we observed a low rate of...

The BPA contract facilitates the sales and distribution of Excellagen across the VA system’s 165 hospitalsExcellagen wound conforming matrix is used to manage wounds including Diabetic Foot Ulcers, that affect a staggering 21% of our veteransMIRAMAR, Fla., March 30, 2020 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) proudly announced that the company’s subsidiary Olaregen Therapeutics’ wound conforming matrix, Excellagen, has been awarded a Blanket Purchase Agreement (BPA) contract from the National Strategic Acquisition Center (SAC) through the efforts of AvMedical, Olaregen’s Small Disabled Veteran Owned Small Distributor (SDVOSD) partner.  The VA’s National Contract and National BPA programs are used by VA medical centers, related facilities, specific...

NEW YORK, March 30, 2020 (GLOBE NEWSWIRE) —Total revenue of $43.2 million compared to $42.7 million in the prior year quarter.GAAP Operating Loss- $59.6 million as compared to $52.1 million in the prior year quarter.Adjusted EBITDA increases 71% from the prior year quarter, while Adjusted EBITDA margin improves to 51% from 30% in the prior year quarter.Signed 191 license deals during 2019, representing $135 million of aggregate guaranteed minimum royalties over the life of these contracts.Improved cost structure of business during the year, decreasing SG&A cost 20% from prior year quarter and 31% year-over-year.Iconix Brand Group, Inc. (Nasdaq: ICON) (“Iconix” or the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2019.Bob Galvin, CEO commented, “Results...

30 March, 2020.Company Announcement 2/2020Nordic Shipholding A/S — Financial calendar 2020 – UpdateDue to COVID-19 and the Danish Government’s ban on gatherings comprising more than 10 people, the annual general meeting is postponed from 23 April 2020 to 4 June 2020.The remaining dates remain unchanged.The updated Financial Calendar for 2020 is as follows:                                               

30. marts 2020.Selskabsmeddelelse 2/2020Nordic Shipholding A/S — Finanskalender 2020 – OpdateringGrundet COVID-19 og regeringens forbud mod forsamlinger med mere end 10 personer er den ordinære generalforsamling udskudt fra den 23. april 2020 til den 4. juni 2020.De øvrige datoer er uforandrede.Den opdaterede Finanskalender for 2020 er som følger:                                                 

 Company Deemed a Critical Industry By Depart of Homeland SecurityPHOENIX, AZ, March 30, 2020 (GLOBE NEWSWIRE) — Taronis Fuels, Inc., (“Taronis” or “the Company”) (OTC: TRNF), a global producer of renewable and socially responsible fuel products, today provided a summary update of domestic operations across all markets. The Company has been deemed a critical industry as classified by the Department of Homeland Security. As a result of this classification, the Company is permitted to maintain fully functioning daily operations in all markets, including Florida, Louisiana, Texas and California. The Company is also fully permitted to conduct interstate business with clients and wholesale distribution partners in the Northeast, Midwest and Mid-Atlantic markets.Despite the uncertainty created by the ongoing Coronavirus pandemic, the...

VANCOUVER, British Columbia, March 30, 2020 (GLOBE NEWSWIRE) — Pender Growth Fund Inc. (TSXV: PTF) and PenderFund Capital Management Ltd. (collectively “Pender”) announce today that, further to its news release dated February 26, 2020, it has completed the second and final tranche of investment, by way of private placement, in GreenSpace Brands Inc. (the “Greenspace”) (TSX-V: JTR), pursuant to the terms of an investment agreement, as amended, entered into between Pender and GreenSpace (the “Amended Investment Agreement”) and subject to final approval of the TSX Venture Exchange (“TSX-V”).Having received conditional approval from the TSX-V and the approval of GreenSpace’s disinterested shareholders in accordance with the rules and policies of the TSX-V, Pender Growth Fund Inc. and other funds managed by PenderFund Capital Management...

 Todos expands rights to include Asian countries and to include PCR test kits Corona Diagnostics JV with Emerald Organic responsible for commercialization Dr. Joseph Wee, CEO of Todos Singapore, will lead Asian commercialization effortREHOVOT, Israel and New York, NY, March 30, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Todos Medical Ltd. (OTCQB: TOMDF), a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that it has expanded its exclusive distribution agreement (the “Distribution Agreement”) with Gibraltar Brothers & Associates, LLC, a US-based subsidiary of Shanghai Liangrun Biomedicine Technology Co., to include polymerase chain reaction (PCR) testing kits in addition to colloidal gold IgM/IgG...

DALLAS, March 30, 2020 (GLOBE NEWSWIRE) — Dave & Buster’s Entertainment, Inc., (NASDAQ:PLAY), (“Dave & Buster’s” or “the Company”), an owner and operator of entertainment and dining venues, today announced that it will report financial results for its fourth quarter 2019 ended on February 2, 2020 on Thursday, April 2, 2020 after the market close.Management will hold a conference call to report these results the same day at 4:00 p.m. Central Time (5:00 p.m. Eastern Time). The conference call can be accessed over the phone by dialing (720) 543-0206 or toll-free (800) 458-4148. A replay will be available after the call for one year beginning at 7:00 p.m. Central Time (8:00 p.m. Eastern Time) and can be accessed by dialing (412) 317-6671 or toll-free (844) 512-2921; the passcode is 7726683.Additionally,...

TORONTO, March 30, 2020 (GLOBE NEWSWIRE) — RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or “RAMM”) (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical products, announces that pursuant to the blanket relief granted by the Canadian Securities Administrators it will not be filing its interim financial statements for the quarter ended January 31, 2020, and  the  related  management’s  discussion  and analysis, as required by Parts 4 and  5 of National Instrument 51-102 – Continuous Disclosure Obligations (collectively, the “Interim Filings”) by the filing deadline of March 31, 2020. The Company expects to report results within the next two weeks, and is afforded a postponement up to a maximum 45-day extension pursuant to blanket relief for all market participants granted...